Nanoform Selects a CDMO Partner for a GMP Biologics Production Line in Germany

project_news

Nanoform Selects a CDMO Partner for a GMP Biologics Production Line in Germany

Updated on Nov 18, 2026, 10:29 PM IST
Written & Edited by Harikesh VA

Helsinki-based Nanoform Finland Plc, the medicine performance-enhancing company, has signed an agreement with a contract development and manufacturing organization (CDMO) for GMP manufacturing of its ultra-high-concentration biologics technology.

 

The announcement describes the deal as an important step in advancing Nanoform's biologics technology towards clinical application.

Nanoform to Establish Biologics Production Line in Germany

The CDMO partner, headquartered in Europe, is described as a global leader in aseptic manufacturing of biologics and can support projects ranging from early clinical to commercial manufacturing.

 

Under the agreement, the parties will establish a dedicated production line for Nanoform's biologics technology within the CDMO's existing aseptic manufacturing facility in Germany.

 

That facility already holds capabilities for the manufacture of injectable biologics under Good Manufacturing Practice (GMP) standards, including aseptic processing and fill-and-finish.

Nanoform and the CDMO partner are targeting GMP readiness during the second half of 2027. The timeline is intended to support a planned first customer clinical trial of a subcutaneous ultra-high concentration suspension biologic product enabled by nanoforming. Nanoform stated that the agreement does not have an immediate material financial effect on the company.

 

An Accelerated Pathway to the Clinic

For Nanoform's customers, the collaboration is positioned as an accelerated pathway from formulation and preclinical development at Nanoform through to GMP manufacture and supply of material for clinical trials and later commercial manufacturing.

 

By combining Nanoform's biologics technology and development capabilities with the CDMO's established aseptic infrastructure, quality systems, and manufacturing expertise, the company says the transition into clinical development is accelerated.

Chief Executive Officer Edward Hæggström welcomed the deal, saying the company is pleased to have identified an excellent partner to enable it to accelerate its customers' entry to clinics with subcutaneous ultra-high concentration suspension products enabled by nanoforming.

 

He added that Nanoform looks forward to the implementation work at the partner's site during the coming months and that both the company and its customers are impressed by the expertise and speed with which the cooperation has started.

Chief Commercial Officer Christian Jones emphasized the importance of clinical supply on the biologics side, saying that enabling clinical supply is fundamental for Nanoform's customers and partners.

 

According to Jones, the partnership will provide an accelerated pathway to clinical supply of GMP material with a CDMO that is a global leader in aseptic manufacturing and has a strong network to support the joint customers.

Trusted by Leading EPCs & Manufacturers

Find the Latest Pharmaceutical Plant Projects in Germany

Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information

Request Free Trial → Learn More →

No credit card Up-to-date coverage

 

Strategic Focus on Subcutaneous Delivery

Nanoform has stated its belief that subcutaneous delivery will become the dominant standard for both new and marketed biologics.

 

The company's suspension formulations are designed to enable high drug concentrations with particle properties that Nanoform describes as critical for suspension performance.

The technology at the center of the agreement is Nanoform's nanoforming platform. The company leverages nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable what it terms superior medicines for patients.

 

Its stated focus is on reducing clinical attrition and enhancing drug molecules' performance through nanoforming technologies and formulation services, spanning from preclinical to commercial scale. Nanoform says its technologies aim to improve bioavailability and drug delivery profiles, drive differentiation and patient adherence, and extend the lifecycle potential of products.

Share Stock and CDMO Partner

Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki under the ticker NANOFH and in Stockholm under the ticker NANOFS. The company's certified adviser is DNB Carnegie Investment Bank AB.

Neither the identity of the CDMO partner nor the financial terms of the agreement were disclosed in the announcement.

Stay Ahead of Germany's Rapidly Evolving Chemical Sector with Real-Time Project Intelligence

What distinguishes top chemical firms from those struggling to keep pace? Access to timely, verified project data across the country. In a market where opportunities emerge and vanish within weeks, depending on fragmented sources is no longer viable.

 

The Global Project Tracking (GPT) platform by Blackridge Research consolidates every major development across the chemical sector in Germany into a single, searchable intelligence hub, so your team spends less time hunting for information and more time acting on it.

 

Whether you're monitoring new chemical projects, awarded contracts, or initiatives nearing completion, the platform provides the insights necessary for making informed, data-driven decisions in the chemical sector.

 

  • Upcoming Projects

  • Tender Notices

  • Contract Awards

  • Projects Under Construction

  • Completed Projects

 

Explore the Global Project Tracking (GPT) platform's capabilities and learn how it can enhance your competitive advantage in Germany's chemical sector. Schedule a Free Demo today.

Tags

Leave a Comment

We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.

We read every comment and do our best to respond to them all.

Protected by Cloudflare Turnstile